Abstract The goal of diagnosing and treating latent tuberculosis infection (LTBI) in children is to prevent future cases of tuberculosis (TB) disease. In low-prevalence countries, LTBI screening, testing, and treatment are risk based. Testing is limited by lack of a reference standard; both available methods-the tuberculin skin test (TST) and interferon gamma release assays (IGRAs)-have significant limitations. The antigens used in IGRAs are not found in BCG-Mycobacterium bovis or most nontuberculous mycobacteria, making these tests more specific for Mycobacterium tuberculosis infection than the TST. The two methods have similar sensitivity, and neither performs well in immunosuppressed children. Children with LTBI are given treatment because it decreases their risk of developing TB disease, and the rate of significant adverse events is low. The most commonly used treatment regimen of 6-9 months of isoniazid is limited in effectiveness by poor adherence. New treatment regimens, using 4 months of rifampin, 3 months of isoniazid and rifampin, or 12 weekly doses of isoniazid and rifapentine, are safe and have significantly higher completion rates.
Introduction
Tuberculosis (TB) remains one of the most common bacterial infections worldwide, as over 1/3 of the world's population is infected with Mycobacterium tuberculosis [1•] . While the overall incidence of TB has decreased significantly in the United States (U.S.) over the past few decades, it disproportionately affects certain high-risk groups, including ethnic minority and immigrant populations [2] . In the U.S., from 2008 to 2010, 2,660 children and adolescents \18 years of age were diagnosed with TB disease, 31 % of whom were foreign-born and 75 % had an international connection through family or residence history [3] . Prior to 2009, children emigrating to the U.S. from foreign countries often received no testing for TB. Some of these children developed disease or were evaluated and treated for TB after immigration, but many have untreated TB infection and are at risk of developing disease later in life. In addition, many children who were infected with M. tuberculosis within the U.S. or abroad have gone undetected. Because of budget cuts, many local health departments are unable to provide TB screening and testing services for high-risk children in the U.S., which is now the responsibility of primary care physicians. Unfortunately, those children at the highest risk for LTBI in the U.S. are often uninsured and lack a primary care physician or medical home, leaving them unscreened, untested, and untreated for TB [2] .
Latent tuberculosis infection (LTBI) means infection with M. tuberculosis as indicated by a positive tuberculin skin test (TST) or interferon-γ release assay (IGRA) test result, a normal physical exam, and a normal chest radiograph. Most patients with untreated LTBI will never develop tuberculosis (TB) disease. The risk of progression from LTBI to disease is highest within the first 6-18 months following initial infection. Otherwise healthy adults have a 5-10 % lifetime risk of progression, while children less than 2 years of age have a 40-50 % risk of progression within 1 year of infection; adolescents have a 10-20 % risk [4••] .
The goal of testing for LBTI is to identify and treat children with epidemiologic factors that put them at risk of being infected with M. tuberculosis and host factors that put them at risk of developing TB disease [5] . In the pediatric population, this includes children who have had recent contact with an infectious person, have a family history of TB disease or infection, have lived or travelled to a high TB-burden country, or have an immunosuppressive disease or are taking immunosuppressive therapy [4••, 5] .
Recent Overview
Recent studies of childhood LTBI have focused on overcoming the difficulties in its diagnosis and treatment. Because of the limitations of the available testing methods, only children with an identified risk factor for TB infection or rapid progression to TB disease should be tested. Determining the absolute sensitivity and specificity of the two available methods of testing for LTBI is difficult because there is no reference standard. Their sensitivity has been estimated in studies of patients with culture-positive disease (absolute proof of infection), while their specificity is estimated by their ability to rule out TB disease in lowrisk populations. Most of the early studies comparing the TST and IGRAs were done in adults, but the number and quality of pediatric studies have increased over the last few years. As expected, the IGRAs are more specific than the TST because the antigens used in IGRAs are not found in BCG-M. bovis or most non-tuberculous mycobacteria (NTM); however, the sensitivity of the IGRAs is no higher and, in some studies, lower than that of the TST.
Once a diagnosis of LTBI has been made, children should be treated to prevent the progression of LTBI to TB disease. Children tolerate LTBI treatment better than adults and the effectiveness of treatment is higher, so the benefits of treatment of pediatric LTBI greatly outweigh the risks. The traditionally used regimens of 6-9 months of isoniazid (INH) are limited in effectiveness by poor adherence to this long-term therapy. Alternative LTBI treatment regimens are now available that offer shorter treatment courses (3-4 months), are well tolerated, and have few associated significant adverse events.
Detection of Latent Tuberculosis Infection (LTBI)
Both the TST and IGRAs are indirect immunodiagnostic tests that measure T cell response to antigens in M.
tuberculosis [4••, 5, 6] . Both methods are considered imperfect in that neither provides a definitive diagnosis of LTBI, neither can distinguish between LTBI and TB disease, and both perform poorly in individuals with immunosuppression, including with advanced TB disease [7, 8] . While both tests are valuable tools to detect LTBI, the interpretation of the results should include a clinical evaluation of the child and the individual's risk factors for TB infection or disease.
Tuberculin Skin Test (TST)
The TST remains the most common diagnostic test for LTBI. It uses PPD (purified protein derivative) tuberculin solution, which is derived from a crude precipitate of more than 200 antigens. The PPD is injected intradermally on the volar surface of the forearm where the antigens stimulate a delayed-type hypersensitivity reaction. Induration (not erythema) is measured along the transverse diameter 48-72 h after placement [4••, 5] . TST results can be difficult to interpret. The placement and interpretation of the induration require 2 visits and should be performed by an experienced individual. The reaction size in an individual host can vary by 15 % between tests and the variability in measuring induration among experienced observers also varies by 15 %, although it is much greater in untrained persons [9] .
The interpretation of the size of a TST induration is based on the individual's risk factors for TB. In individuals whose likelihood of infection is low, specificity takes precedence and an induration of ≥15 mm is considered positive. In those at lower risk, but with an identified risk factor for LTBI, induration ≥10 mm is considered positive. In individuals at highest risk of having LTBI progress to disease (clinical evidence of disease, recent exposure, or immunocompromise), TST sensitivity is paramount, and a reaction ≥5 mm is considered positive [4••] .
TST induration can be caused by infection with M. tuberculosis, exposure to NTM, or previous BCG vaccination [10, 11] . The patient's history and the size of the induration often help determine the cause of the reaction. Most individuals exposed to NTM have indurations \10 mm, but larger reactions can occur. The most effective way to minimize false-positive results is to avoid testing individuals without a known risk factor for TB.
The bacillus Camille-Guerin (BCG) vaccine is given to infants in high TB-burden countries to reduce the risk of severe forms of TB disease. Many of the antigens in PPD are also expressed by BCG M. bovis, and some vaccinated individuals who are not infected with M. tuberculosis express induration in response to the TST. BCG causes induration ranging from 0 to 19 mm, and the effect wanes with time. When BCG is given to school-age children and adults, they can retain reactivity for 5-10 years [11] [12] [13] [14] [15] . TST specificity in BCG-unvaccinated children is estimated to be 95-100 %. In BCG-vaccinated children, specificity falls to 49-65 %, leading to many false-positive results [16] .
False-negative TST results also occur in individuals who are unable to mount an adequate immune response. This group includes children who are immunosuppressed by disease (such as advanced HIV infection, advanced TB, cancer, or malnutrition), who receive immunosuppressive treatments (such as corticosteroids, cancer chemotherapy, and immunomodulating agents, especially tumor necrosis factor (TNF) alpha inhibitors), or who recently received a vaccination with live-virus vaccine (particularly, the measles vaccine). The QFT is an enzyme-linked immunosorbent assay (ELISA) whole blood test that quantifies the amount of INF-γ released by sensitized T-cells in response to three antigens. Assays are considered positive if the amount of INF-γ in the test sample, after subtracting the amount in the negative control, exceeds a cut-off of ≥0.35 IU (International Units)/milliliter. If there is no detectable INF-γ response to the positive control or if the INF-γ level in the negative control is too high, the sample is deemed "indeterminate," neither positive nor negative. T-SPOT is an enzyme-linked immunosorbent spot (ELISPOT)-based test that quantifies the number of mononuclear cells producing INF-γ in response to two antigens. The result is reported as the number of INF-γ-producing T-cells. Assays are considered positive if the number of spots in the test sample, after subtracting the number of spots in the negative control, exceeds a threshold, usually 8 spots. Assays with ≤5 spots are considered negative. Assays with 6-7 spots are considered borderline (equivocal), requiring retesting. If the positive control assay has a poor response to stimulation, or if the negative control response is too high, the result is considered "invalid," neither negative nor positive [4••, 7] .
IGRA Performance in Adults
The test performance of IGRAs was first studied in adults. As there is no reference standard test for LTBI, specificity was estimated in low-risk individuals in a low-prevalence setting. Several studies and meta-analyses have demonstrated IGRA specificity of 95-100 %, and unlike the TST, it is not influenced by prior BCG vaccination [17, 18••, 19] . IGRA sensitivity is best estimated among culture-confirmed cases of TB disease (absolute proof of infection). The sensitivity of IGRAs in adults with culture-confirmed disease is comparable to TSTs at 60-90 % (TST sensitivity is 80 %) with a slight favoring of T-SPOT over QFT. The sensitivity of IGRAs, similar to the TST, is lower in individuals with immunodeficiency. In a meta-analysis evaluating the use of IGRAs compared to the TST in HIVinfected adults, the T-SPOT was slightly more sensitive than QFT (72 vs. 61 %), but neither was more sensitive than the TST [20] .
IGRA Performance in Children
Fewer studies have evaluated the sensitivity and specificity of IGRAs in children. Because it is difficult to microbiologically diagnose TB disease in children, gradients of exposure to an infectious adult are often used as a surrogate for likelihood of infection to evaluate IGRA performance.
Four systemic reviews and meta-analyses examined IGRA performance in children [ 
Each analysis was limited by study method heterogeneity and variable clinical definitions of TB. In their meta-analysis, Sun and colleagues included 7 studies that evaluated IGRA specificity in immunocompetent children (0-100 % were BCG vaccinated) [22••] . IGRA specificity was 89 % for BCG-vaccinated children and 95 % for unvaccinated children. TST specificity was 49 % for BCG-vaccinated children and 93 % for unvaccinated children. The percent agreement between the IGRAs and TST was higher in the BCG-unvaccinated children likely due to the influence of false-positive TST results caused by the BCG vaccine. Among 207 children (36 % of whom were BCG vaccinated) with TB risk factors in New York City, only 23 % of children with a positive TST had a positive QFT. QFT better correlated with increased risk of exposure than TST [25] . The influence of gradient of exposure and QFT positivity was also confirmed in a study involving 227 BCGvaccinated children in South Korea [26] . The rate of QFT positivity in unexposed children was 1.5 %, compared to a rate of 6.9 % in children with casual contact, and 19 % in those with a close contact with TB disease. In the unexposed children (considered at lowest risk of LTBI), QFT specificity was high (95.5 %). The summary of all the published studies is that the IGRAs are more specific than the TST for children, and the use of IGRAs is favored over the TST in BCG-vaccinated individuals, leading to fewer false-positive results [ The evaluation of IGRA sensitivity compared to the TST in children is far more challenging, and the best information comes from the pooled data for TB disease diagnosed by culture or clinically, which are included in the pediatric meta-analyses. In children with culture-confirmed disease, Sun and colleagues found a pooled sensitivity of 85 % for QFT, 76 % for T-SPOT, and 85 % for the TST. In individuals who were diagnosed clinically with TB disease, sensitivity was lower for all the three tests (QFT-64 %, T-SPOT-58 %, and TST-66 %) [22••] . Although this meta-analysis found no significant difference in test performance between high and low TB-burden settings, two other meta-analyses found the sensitivity of IGRAs to be lower in high burden settings, the number of subjects was small [23••, 24••] . The sum of all published studies suggests that the IGRAs are not more sensitive than the TST (likely less sensitive in high burden settings) or other measures of determining TB disease in children and cannot be used to rule out TB disease. However, sensitivity for detecting LTBI and TB disease is increasedat the expense of specificity-when both a TST and IGRA are performed (either test being positive), and the use of both tests will increase the rate of positive results in high-risk patients [29] .
IGRA Limitations
Rates of indeterminate/invalid results among children have varied between 0 and 35 %, but most studies reported a range of 0-10 % [7, 24••, 30•, 31•, 32, 33] . The rates seem to be lower with advancements in test technique. Rates of indeterminate/invalid results are increased in children who are immunocompromised (especially with HIV infection), who have poorly controlled inflammatory bowel disease, and who have certain co-infections, including hepatitis, malaria, and helminth infection [34] [35] [36] [37] . Indeterminate/invalid IGRA results also occur due to technical error (wrong volume, insufficient mixing, incorrect temperature, prolonged time prior to processing, and laboratory error) [30•, 31•] .
There has also been conflicting evidence regarding the performance of IGRAs in infants and children \5 years of age, which is thought to be related to an impaired immune response to M. tuberculosis in this age group. This is potentially problematic as young children, especially those \2 years of age, are at greatest risk of progression to severe forms of TB disease [16, [39•] . A trend toward lower QFT sensitivity was observed in the \2 years group (60 %) compared to the 2-5 years group (100 %), but it did not reach statistical significance (p = 0.087). More recent studies have demonstrated better performance of IGRAs in young children. A study in Croatia evaluated 142 healthy BCG-vaccinated children with QFT and the TST following exposure to an infectious adult [30•] . Twenty-four children (17 %) had a positive TST, and 18 (13 %) children had a positive IGRA. Overall test concordance was high (89 %, κ = 0.591). In a sub-group analysis, the concordance between QFT and TST among children \2 years of age was even higher (95 %, κ = 0.828). QFT and TST results were both associated with the degree of exposure. In summary, it appears that the indeterminate/invalid rates are higher in infants and toddlers, but the sensitivity of the IGRAs in these young children has not yet been firmly established.
Current Recommendations for LTBI Testing
Some of the major differences between the TST and IGRAs are listed in Table 1 . The current recommendations for testing children for LTBI are summarized in Table 2 Unfortunately, performing randomized controlled trials of new LTBI regimens for children is difficult and expensive. As a result, most of the information for newer regimens comes from studies performed in adults. It has become the consensus among many childhood TB experts that regimens that are effective for treating TB disease and LTBI in adults are likely to be at least equally effective in children; the essential pediatric data are for pharmacokinetics of drugs, safety, tolerability, adherence to treatment, and completion rates of the regimen. There are several alternative treatment regimens for LTBI that can be considered for children (Table 3) .
Isoniazid (INH)
Isoniazid (INH) is the most extensively studied therapy for the treatment of LTBI in both children and adults. The initial randomized controlled trial of INH therapy was conducted by the United States Public Health Service (USPHS) in the 1950s [44] [45] [46] [47] . This trial compared the efficacy of two doses (1.25 vs. 5 mg/kg) and two frequencies (daily or 5 times weekly) of INH given for 12 months. There was a 90 % reduction in TB disease in individuals taking INH 5 mg/kg either daily or 5 times weekly, a protection that plateaued between 6 and 9 months duration. Further evidence to support INH therapy in children was found by Hsu, who followed a cohort of 1,881 children in Houston with LTBI during and after a 12-month course of daily INH (10 mg/kg); only 8 children developed TB disease (rate 4.2/1,000) over 30 years, for a protective efficacy of 99 % [48] .
Isoniazid, 6 Versus 9 months
Additional trials have studied the duration of INH therapy. The Scientific Committee on Prophylaxis of the The initial TST is positive and:
The child is ≥5 years of age and BCG vaccinated
Additional evidence is needed to support an LTBI diagnosis
The initial TST or IGRA is negative and:
There is concern for TB disease
The child is at risk of rapid progression of LTBI to TB disease TST tuberculin skin test, IGRA interferon gamma release assay, BCG bacillus Camille-Guerin, LTBI latent tuberculosis infection,
TB Mycobacterium tuberculosis
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International Union Against Tuberculosis (IUAT) compared the efficacy of 3-, 6-, and 12-month regimens of INH in 28,000 adult patients with LTBI and fibrotic lesions on chest radiograph [49] . Over 5 years of observation, subjects taking the 12-month regimen had the lowest risk of TB disease (0.1 %), followed by those taking therapy for 6 months (0.5 %), and 3 months (1 %), compared with subjects taking a placebo (1.4 % risk). A review of the data from the UHPHS INH trial showed that 9 months of therapy had a 20 % increased rate of protection compared with 6 months of therapy [46] . However, a Cochrane review of 11 studies involving over 70,000 subjects found no difference in efficacy between 6 and 12 months of INH therapy given daily [50] . Serious adverse events associated with INH are extremely uncommon in children. An extensive meta-analysis found that of 8,979 children receiving INH (10-20 mg/kg/ day), 25 (6.8 %) of 369 children having routine laboratory evaluation had asymptomatic mildly increased liver enzymes; one child (0.003 %) developed jaundice and 68 children (0.18 %) developed clinical signs of hepatotoxicity; however, treatment had to be discontinued in only 2 children (0.005 %) [55••] . INH also can cause peripheral neuropathy, which manifests initially as tingling in the distal extremities, caused by increased excretion of pyridoxine (vitamin B6). It is rare in children but more common in adolescents; children with diabetes, malnutrition, or advanced HIV infection; and in breastfeeding infants. These children should be given pyridoxine supplementation when taking INH [6] .
Rifampin (RIF)
Several studies have examined the efficacy, safety, and tolerability of RIF monotherapy for LTBI in adults [56] [57] [58] . Two small randomized controlled trials comparing the efficacy of 4 months of RIF (10 mg/kg up to 600 mg/ dose) to 9 months of INH (5 mg/kg up to 300 mg/dose) in adults showed comparable efficacy, with improved completion of therapy with RIF (78-81 %) compared with INH (60-76 %) [57, 58] . No pediatric randomized controlled trials for RIF therapy have been reported; the data are limited to two pediatric observational studies [59, 60] . RIF therapy was used in a high school in California to treat 157 students with LTBI after their exposure to a classmate with an INH-resistant strain of TB. The students were treated with 6 months of RIF, which was administered 5 days a week at school. After a 2-year follow-up period, no students developed TB disease [59] . More recently, an observational study from Philadelphia compared completion rates between RIF therapy (either 4 or 6 months) and INH therapy (9 months) administered daily at home by the families [60] . Children receiving 4 months of RIF were more likely (80.5 %) to complete treatment than those taking INH (53.1 %). This study did not evaluate the efficacy of 6 months versus 4 months of RIF; however, several observational studies in adults suggest a high efficacy associated with 4 months of RIF therapy [61] [62] [63] [64] [65] .
RIF Adherence and Side Effects
The studies of adults have shown improved adherence with and better tolerance of RIF regimens compared with INH [61] [62] [63] [64] [65] . A large retrospective study involving over 2,000 adults showed that completion rates of RIF therapy given for 4-6 months were three times higher than for 9 months of INH and patients on RIF [65] . In the two observational studies involving children, the RIF regimens were directly observed, leading to excellent adherence rates (88-94 %) [59, 60] .
Adverse events associated with RIF are infrequent in both adults and children [59] [60] [61] [62] [63] [64] [65] . In the large retrospective study involving over 2,000 adult patients, 11.3 % of patients taking 9 months of INH developed any adverse reaction compared to 8.3 % taking RIF (p = 0.2), and 1.8 % of patients taking INH versus 0.08 % of patients taking RIF developed hepatotoxicity (p \ 0.001) [65] . A large retrospective study from Switzerland included 624 adult patients with LTBI and compared rates of hepatotoxicity (defined as AST or ALT elevation ≥3 times the upper limit of normal with symptoms or ≥5 times the upper limit of normal if asymptomatic) leading to treatment discontinuation [61] . Seven patients out of 426 (1.6 %) taking INH had AST/ALT elevations ≥3 times the upper limit of normal with symptoms compared to 0 patients taking RIF. Elevations of AST/ALT ≥5 times the upper limit of normal occurred in 19 patients taking INH (4.5 %) compared to 4 patients out of 198 taking RIF (2 %). Hepatotoxicity leading to an interruption of therapy occurred more often in patients taking INH (6.1 %) compared to RIF (2 %) [61] . In the California observational trial involving 157 adolescents, 4 students (1.3 %) taking RIF had ALT elevations ≥2 times the upper limit of normal which led to a discontinuation of therapy [59] . Minor adverse events occurred in 41 (26 %) students including staining of secretions an orange color, mild skin rashes, gastrointestinal complaints, headaches and dizziness, blurred vision, bruising, and nausea and fatigue. Six students had low platelet counts (minimum count of 101 9 10 3 /mm 3 ), and none experienced symptomatic bleeding. Only 18 students who experienced these adverse events temporarily stopped therapy, and only 2 had permanent discontinuation.
The AAP currently recommends 4-6 months of RIF therapy for children with LTBI who have been exposed to an INH-resistant source case (Table 3 ) [4••] . However, RIF therapy also should be effective for treating a pan-susceptible M. tuberculosis infection and there is no inherent reason to limit its use to INH-resistant cases. Prior to the initiation of RIF therapy, a practitioner must consider the following: the high cost of RIF compared with INH (INH is $4/month at many pharmacies) and the risk of drug-drug interactions. Rifamycins induce the cytochrome CYP-450 system, which increases the metabolism of certain oral contraceptives, anti-epileptic medications, antiretroviral medications, and other medications. Rifamycins should, therefore, be used with caution in patients taking any medication with a potential interaction.
Isoniazid and Rifampin
The combination of INH and RIF given daily for 3-4 months for treatment of LTBI is used mainly within Europe. Trials performed in both adults and children have evaluated the efficacy and safety of daily INH + RIF regimens compared to INH monotherapy [66] [67] [68] . A meta-analysis included 5 randomized controlled trials with 1,900 adult patients with LTBI and compared the efficacy and safety of 9 months of INH to 3 months of INH + RIF [66] . The authors found no difference in efficacy between the two regimens; 39 patients (4.1 %) who received INH versus 41 patients (4.2 %) who received INH + RIF developed TB disease. The two regimens also had comparable safety: 46 patients (4.8 %) who received INH and 48 (4.9 %) of patients who received INH + RIF developed adverse effects leading to discontinuation of therapy (including hepatotoxicity, rash, and gastrointestinal intolerance). Among 252 patients with LTBI in the British medical system who received 3 months of INH + RIF treatment, and were followed for up to 19 years, only 3 cases of TB disease occurred, a rate of 0.727 cases/1,000 person years [67] .
A randomized study in Greece involved 926 children \15 years of age with LTBI who were treated with 9 months of daily INH versus either 3 or 4 months of INH + RIF [68] . Of the children who took 9 months of INH monotherapy, 48 (24 %) developed new radiographic findings (including hilar adenopathy or parenchymal disease) suggestive of possible active disease, compared to 26 (11.8 %) on 3 months of INH + RIF. These are extremely high rates for both groups and most of the chest radiograph changes were subtle, asymptomatic and resolved without a change in therapy. Patients who took 3 months of INH + RIF had significantly higher rates of adherence to treatment (78-90 %) than those taking INH monotherapy (66 %). Twelve of 200 (6 %) children receiving INH monotherapy had mild liver enzyme elevations (\3 times the upper limit of normal), compared to 8 of 650 patients (1.2 %) taking INH + RIF. No children experienced any adverse events during the study leading to a discontinuation of therapy (Table 3) .
Isoniazid and Rifapentine
Rifapentine (RFP) is a new rifamycin with a longer halflife (12) (13) (14) (15) [72] .
In this trial, individuals in the INH group were more likely than those in the INH + RFP group to develop hepatotoxicity leading to discontinuation of therapy (2 vs. 0.3 %, [p \ 0.01]). Individuals in the INH + RFP group were slightly more likely to discontinue therapy secondary to hypersensitivity reactions associated with the RFP [71••] . In children ages 2-11 years of age, no significant differences in the number or severity of adverse reactions were observed between the two treatment regimens (Table 3 ) [72] .
In summary, 12 weekly doses of INH + RFP given via DOT are a safe and well-tolerated regimen for the treatment of LTBI children [2 years of age. Because the efficacy data are stronger for older children, it is currently recommended by the AAP and CDC for treatment of LTBI in patients ≥12 years of age and can be used with caution in children ages 2-11 years [73] . Studies are underway to determine if INH + RFP can be given effectively and safely by self-supervision.
LTBI Treatment: Conclusions
Children are treated for LTBI to decrease their risk of developing TB disease in both the near and distant future. Treatment is highly effective when taken as planned and the rate of significant adverse events is low. The most commonly used treatment regimen of 6-9 months of isoniazid, while highly efficacious in clinical trials, is limited in effectiveness by poor adherence and low completion rates. New treatment regimens, using 4-6 months of daily rifampin, 3 months of daily isoniazid and rifampin, or 12 once weekly doses of isoniazid and rifapentine under DOT, are safe in children and have significantly higher completion rates. Prior to the initiation of LTBI therapy, a practitioner must consider a variety of factors which may affect the likelihood of the child successfully tolerating and completing the chosen regimen. These include medication availability, insurance coverage, medication cost, the time frame available to the family for treatment completion, and the susceptibility of the source case's M. tuberculosis isolate. Given the low frequency of serious adverse events associated with LTBI therapies, routine laboratory monitoring is not recommended for any regimen in an otherwise healthy child [4••, 74] ; rather, educating patients and parents about potential adverse events and clinical screening for signs and symptoms of adverse events at regular follow-up visits should be adequate. Children at risk of hepatotoxicity, especially those with existing liver disease or taking other potentially liver toxic medications, should be followed periodically both clinically and with measurement of serum liver enzymes [74, 75] .
Conclusion
Both the TST and IGRAs can be used as tools to diagnose LTBI in children with known risk factors for TB. It is clearly established that the IGRAs are more specific than the TST because they are not influenced by prior BCG vaccination or exposure to most NTM. The TST and IGRAs have comparable sensitivity in older children but there is some concern about their sensitivity in infants and toddlers. As a result, for children less than 4 years of age, TSTs generally are preferred over IGRAs. Sensitivity can be maximized in high-risk children using both methods. However, this will result in decreased specificity and some false-positive results. In children who are immunocompromised by medical conditions or therapy, both the TST and the IGRAs have diminished sensitivity, and the rate of indeterminate/invalid results in the IGRA tests will be increased. Recent studies have identified several treatment regimens for LTBI that have certain advantages over the traditional 6-9 month course of self-supervised INH. These shorter regimens using a rifamycin with or without INH are safe, well tolerated, and result in higher completion rates than seen with the 9-month INH regimen. Efficacy data for these new regimens are not as robust, but current indications are that they are effective, and the increased adherence and completion rates would off-set any small decrease in efficacy. 
